---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-21-007561"
form_type: "8-K"
ticker: "ALGS"
cik: "0001799448"
company_name: "Aligos Therapeutics, Inc."
filed_at: "2021-11-04T23:59:59+00:00"
generated_at: "2026-06-28T13:15:50.282036+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Aligos Q3 net loss $33.1M ($0.78 loss per share); clinical programs advance

## Summary
- Net loss $33.1M, EPS $(0.78) vs net loss $33.3M, EPS $(11.00) in Q3 2020.
- R&D expenses $28.1M (up from $17.3M) on continued development of three CHB candidates and NASH drug.
- Cash, cash equivalents and investments $242.7M as of Sep 30, 2021, down slightly from $243.5M.
- Dosing of ASO candidate ALG-020572 in healthy volunteers started; STOPS cohorts (120, 200 mg) fully enrolled.
- CTA filed for NASH candidate ALG-055009 (THR-β agonist); dosing in healthy volunteers expected Q4 2021.

## SEC filing metadata
- accession: 0001171843-21-007561
- form_type: 8-K
- ticker: ALGS
- cik: 0001799448
- company_name: Aligos Therapeutics, Inc.
- filed_at: 2021-11-04T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1799448/000117184321007561/0001171843-21-007561-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1799448/000117184321007561/f8k_110421.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-21-007561
- JSON: https://secwatch.observer/filing/0001171843-21-007561.json
- Plain text: https://secwatch.observer/filing/0001171843-21-007561.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.